Expression of Fas ligand in liver metastases of human colonic adenocarcinomas.

Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Gut (1999) 1.75

Human melanoma cells do not express Fas (Apo-1/CD95) ligand. Cancer Res (1999) 1.55

HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest (1998) 1.49

Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol (1999) 1.26

Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer (2004) 1.20

Fas ligand upregulation is an early event in colonic carcinogenesis. J Clin Pathol (2001) 1.07

FasL is more frequently expressed in liver metastases of colorectal cancer than in matched primary carcinomas. Br J Cancer (1999) 1.06

Fas ligand mediates immune privilege and not inflammation in human colon cancer, irrespective of TGF-beta expression. Br J Cancer (2003) 1.03

The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res (2011) 0.99

Differential expression of cell cycle and apoptosis related proteins in colorectal mucosa, primary colon tumours, and liver metastases. J Clin Pathol (2002) 0.98

Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege. Clin Diagn Lab Immunol (1999) 0.97

T cell-tumor cell: a fatal interaction? Cancer Immunol Immunother (1998) 0.97

Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasms. Br J Cancer (2000) 0.96

ARK5 expression in colorectal cancer and its implications for tumor progression. Am J Pathol (2004) 0.95

The status of Fas and Fas ligand expression can predict recurrence of hepatocellular carcinoma. Br J Cancer (2000) 0.95

Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines. Proc Natl Acad Sci U S A (2001) 0.94

Colchicine protects mice from the lethal effect of an agonistic anti-Fas antibody. J Clin Invest (2000) 0.92

The p42 variant of ETS1 protein rescues defective Fas-induced apoptosis in colon carcinoma cells. Proc Natl Acad Sci U S A (1999) 0.90

Proapoptotic effect of proteolytic activation of matrix metalloproteinases by Streptococcus pyogenes thiol proteinase (Streptococcus pyrogenic exotoxin B). Infect Immun (2004) 0.90

Fas ligand is present in tumors of the Ewing's sarcoma family and is cleaved into a soluble form by a metalloproteinase. Am J Pathol (1998) 0.89

Fas and Fas-ligand expression in human pancreatic cancer. Ann Surg (2000) 0.88

Tissue microarray analysis of Fas and FasL expressions in human non-small cell lung carcinomas; with reference to the p53 and bcl-2 overexpressions. J Korean Med Sci (2005) 0.88

CD95 (Fas/APO-1)/CD95L in the gastrointestinal tract: fictions and facts. Virchows Arch (2003) 0.86

Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer (2000) 0.86

The presence of anti-p53 antibodies in sera prior to thoracic surgery in non small cell lung cancer patients: its implications on tumor volume, nodal involvement, and survival. Neoplasia (2003) 0.86

Overexpression of HBxAg in hepatocellular carcinoma and its relationship with Fas/FasL system. World J Gastroenterol (2003) 0.82

Bcl-2 expression related to altered p53 protein and its impact on the progression of human pancreatic carcinoma. Br J Cancer (1999) 0.82

Fas ligand expression in colon cancer: a possible mechanism of tumor immune privilege. World J Gastroenterol (2005) 0.81

Effects of DNA methylation on expression of tumor suppressor genes and proto-oncogene in human colon cancer cell lines. World J Gastroenterol (2003) 0.81

Human FasL gene is a target of β-catenin/T-cell factor pathway and complex FasL haplotypes alter promoter functions. PLoS One (2011) 0.81

Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies. BMC Cancer (2013) 0.80

Augmentation of tumor necrosis factor family-induced apoptosis by E3330 in human hepatocellular carcinoma cell lines via inhibition of NF kappa B. World J Gastroenterol (2005) 0.79

Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization. World J Gastroenterol (2005) 0.78

Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice. Br J Cancer (2001) 0.78

Prognostic value of the Fas/Fas ligand system in breast cancer. Contemp Oncol (Pozn) (2013) 0.77

The cancer stem cell: evidence for its origin as an injured autoreactive T cell. Mol Cancer (2006) 0.77

Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells. Ann Surg Innov Res (2009) 0.76

Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas. Int J Clin Exp Pathol (2015) 0.75

Hairpin ribozyme-antisense RNA constructs can act as molecular Lassos. Nucleic Acids Res (2008) 0.75

Retracted Clinicopathological significance of Fas and Fas ligand expressions in esophageal cancer. Am J Cancer Res (2015) 0.75

Selective suppression of cytokine secretion in whole blood cell cultures of patients with colorectal cancer. Br J Cancer (1998) 0.75

Role of cytokines in promoting immune escape of FasL-expressing human colon cancer cells. World J Gastroenterol (2005) 0.75

Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 114.35

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell (1996) 23.99

A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods (1991) 16.64

Apoptosis by death factor. Cell (1997) 14.42

The Fas death factor. Science (1995) 13.81

The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell (1991) 10.96

Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell (1991) 9.73

Lethal effect of the anti-Fas antibody in mice. Nature (1993) 9.20

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell (1993) 9.06

Autocrine T-cell suicide mediated by APO-1/(Fas/CD95) Nature (1995) 8.23

Fas ligand-induced apoptosis as a mechanism of immune privilege. Science (1995) 8.23

A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J Exp Med (1989) 7.07

Transcription of the dystrophin gene in human muscle and non-muscle tissue. Nature (1988) 7.00

Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature (1995) 6.85

A role for CD95 ligand in preventing graft rejection. Nature (1995) 6.07

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (1996) 6.02

Critical factors in the biology of human cancer metastasis: twenty-eighth G.H.A. Clowes memorial award lecture. Cancer Res (1990) 5.41

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion? Nat Med (1996) 5.09

Fas and Fas ligand: lpr and gld mutations. Immunol Today (1995) 4.69

Fas ligand mediates activation-induced cell death in human T lymphocytes. J Exp Med (1995) 4.34

The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice. Immunity (1994) 4.26

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med (1996) 3.56

Fas and FasL in the homeostatic regulation of immune responses. Immunol Today (1995) 3.24

Involvement of the CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med (1995) 3.20

Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol (1986) 2.93

Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J (1995) 2.87

The CTL's kiss of death. Cell (1995) 2.80

Human Fas ligand: gene structure, chromosomal location and species specificity. Int Immunol (1994) 2.74

Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review. Br J Cancer (1974) 2.54

Fas ligand in human serum. Nat Med (1996) 2.53

In vivo selection of highly metastatic cells from surgical specimens of different primary human colon carcinomas implanted into nude mice. Cancer Res (1988) 2.36

Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity (1994) 2.21

Contenders in FasL/TNF death signaling. Cell (1995) 2.21

Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res (1994) 1.90

Antitumor effect of locally produced CD95 ligand. Nat Med (1997) 1.82

Die and let live: eliminating dangerous lymphocytes. Cell (1996) 1.64

Fas-mediated apoptosis in primary cultured mouse hepatocytes. Exp Cell Res (1994) 1.41

Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun (1994) 1.39

Origin and biology of cancer metastasis. Cytometry (1989) 1.39

Human tumor-infiltrating lymphocytes: a marker of host response. Semin Hematol (1985) 1.38

Unraveling immune privilege. Science (1995) 1.34

Current concepts in metastasis. Gut (1994) 1.21

Liver colonization competence governs colon cancer metastasis. Proc Natl Acad Sci U S A (1995) 1.17

Cellular events in Fas/APO-1-mediated apoptosis in JURKAT T lymphocytes. Exp Cell Res (1995) 1.09

Human tumor cell heterogeneity and metastasis. J Clin Oncol (1983) 1.01

Cell-mediated cytotoxicity. Cell (1993) 0.99

Local immunity and metastasis of colorectal carcinoma. Dis Colon Rectum (1992) 0.86

Tumor cells fight back to beat immune system. Science (1996) 0.78

The complete genome sequence of the gram-positive bacterium Bacillus subtilis. Nature (1997) 33.47

Primary structure of Electrophorus electricus sodium channel deduced from cDNA sequence. Nature (1984) 8.02

Existence of distinct sodium channel messenger RNAs in rat brain. Nature (1986) 7.87

Differences in diagnostic criteria for gastric carcinoma between Japanese and western pathologists. Lancet (1997) 7.59

Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med (1996) 7.09

Primary structure of the receptor for calcium channel blockers from skeletal muscle. Nature (1987) 6.66

Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med (1994) 6.59

Heterozygous germ line hCHK2 mutations in Li-Fraumeni syndrome. Science (1999) 5.09

Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor. Nature (1986) 4.97

Animal model of axonal Guillain-Barré syndrome induced by sensitization with GM1 ganglioside. Ann Neurol (2001) 4.96

Heterogeneity of the principal sigma factor in Escherichia coli: the rpoS gene product, sigma 38, is a second principal sigma factor of RNA polymerase in stationary-phase Escherichia coli. Proc Natl Acad Sci U S A (1993) 4.92

Epithelioid cell cultures from rat small intestine. Characterization by morphologic and immunologic criteria. J Cell Biol (1979) 4.86

Glucose transport in isolated brush border membrane from rat small intestine. J Biol Chem (1973) 4.75

Structural homology of Torpedo californica acetylcholine receptor subunits. Nature (1983) 4.70

Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J (2009) 4.63

Unstable expansion of CAG repeat in hereditary dentatorubral-pallidoluysian atrophy (DRPLA). Nat Genet (1994) 4.36

Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity. Science (2001) 4.13

Proposal for a new clinical entity, IgG4-positive multiorgan lymphoproliferative syndrome: analysis of 64 cases of IgG4-related disorders. Ann Rheum Dis (2008) 3.77

Primary structure of alpha-subunit precursor of Torpedo californica acetylcholine receptor deduced from cDNA sequence. Nature (1982) 3.69

Rat intestinal microvillus membranes. Purification and biochemical characterization. Biochem J (1968) 3.66

Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet (1997) 3.66

Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain (2007) 3.64

Sequence of 3,687 nucleotides from the 3' end of Sendai virus genome RNA and the predicted amino acid sequences of viral NP, P and C proteins. Nucleic Acids Res (1983) 3.62

Initiation of Sendai virus multiplication from transfected cDNA or RNA with negative or positive sense. Genes Cells (1996) 3.41

Uptake and transport of macromolecules by the intestine. Possible role in clinical disorders. Gastroenterology (1974) 3.33

The pathogenesis of arthritis associated with viral hepatitis. Complement-component studies. N Engl J Med (1971) 3.31

Primary structure of the alpha-subunit of transducin and its relationship to ras proteins. Nature (1985) 3.28

Cloning and sequence analysis of cDNA for porcine beta-neo-endorphin/dynorphin precursor. Nature (1982) 3.09

Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet (1996) 3.07

Germ-line BRCA1 mutations in Jewish and non-Jewish women with early-onset breast cancer. N Engl J Med (1996) 3.04

Modified formalin test: characteristic biphasic pain response. Pain (1989) 3.00

Risk factors for chronic kidney disease in a community-based population: a 10-year follow-up study. Kidney Int (2006) 3.00

Host range, replicative, and cytopathic properties of human immunodeficiency virus type 1 are determined by very few amino acid changes in tat and gp120. J Virol (1991) 2.87

Intestinal uptake of macromolecules: effect of oral immunization. Science (1972) 2.80

Cloning and sequence analysis of cDNA for bovine adrenal preproenkephalin. Nature (1982) 2.79

A consensus linkage map of the chicken genome. Genome Res (2000) 2.79

Cloning and sequence analysis of calf cDNA and human genomic DNA encoding alpha-subunit precursor of muscle acetylcholine receptor. Nature (1983) 2.78

Selective reduction of T cells bearing invariant V alpha 24J alpha Q antigen receptor in patients with systemic sclerosis. J Exp Med (1995) 2.63

Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumors. Cancer Res (1994) 2.61

Determination of the complete nucleotide sequence of the Sendai virus genome RNA and the predicted amino acid sequences of the F, HN and L proteins. Nucleic Acids Res (1986) 2.60

Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci U S A (1990) 2.59

Deleted HTLV-I provirus in blood and cutaneous lesions of patients with mycosis fungoides. Science (1991) 2.56

Primary structures of beta- and delta-subunit precursors of Torpedo californica acetylcholine receptor deduced from cDNA sequences. Nature (1983) 2.55

Cloning and nucleotide sequence of phoP, the regulatory gene for alkaline phosphatase and phosphodiesterase in Bacillus subtilis. J Bacteriol (1987) 2.52

Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med (1999) 2.51

A spin-valve-like magnetoresistance of an antiferromagnet-based tunnel junction. Nat Mater (2011) 2.47

Small intestinal permeability to macromolecules. Transmission of horseradish peroxidase into mesenteric lymph and portal blood. Lab Invest (1971) 2.46

Biogenesis of intestinal plasma membrane: posttranslational route and cleavage of sucrase-isomaltase. Proc Natl Acad Sci U S A (1979) 2.45

Increased uptake of amino acids and 2-deoxy-D-glucose by virus-transformed cells in culture. Proc Natl Acad Sci U S A (1972) 2.41

Periodic emission from the gamma-ray binary 1FGL J1018.6-5856. Science (2012) 2.40

Location of functional regions of acetylcholine receptor alpha-subunit by site-directed mutagenesis. Nature (1985) 2.40

Primary structure of rat brain sodium channel III deduced from the cDNA sequence. FEBS Lett (1988) 2.39

RNA packaging signal of human immunodeficiency virus type 1. Virology (1992) 2.38

Structure of the 5' upstream region and the regulation of the rpoS gene of Escherichia coli. Mol Gen Genet (1994) 2.38

Circulating immune complexes and complement activation in primary biliary cirrhosis. N Engl J Med (1978) 2.30

Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30

Increased expression of eukaryotic translation initiation factors eIF-4E and eIF-2 alpha in response to growth induction by c-myc. Proc Natl Acad Sci U S A (1993) 2.29

Predominant CD4 T-lymphocyte tropism of human herpesvirus 6-related virus. J Virol (1989) 2.28

Reversal of oncogenesis by the expression of a major histocompatibility complex class I gene. Science (1985) 2.22

Small intestinal absorption of horseradish peroxidase. A cytochemical study. Lab Invest (1971) 2.20

Human papillomavirus DNA sequences in esophagus squamous cell carcinoma. Gastroenterology (1994) 2.20

Inorganic polyphosphate and the induction of rpoS expression. Proc Natl Acad Sci U S A (1997) 2.19

Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol (1991) 2.17

Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression. Proc Natl Acad Sci U S A (1999) 2.17

Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett (1998) 2.14

The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis. Complement activation and characterization of circulating immune complexes. J Clin Invest (1975) 2.13

Identification of Rap1 as a target for the Crk SH3 domain-binding guanine nucleotide-releasing factor C3G. Mol Cell Biol (1995) 2.10

Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. J Clin Invest (1999) 2.09

An autopsy case of troglitazone-induced fulminant hepatitis. Diabetes Care (1998) 2.08

Glycoprotein composition of colonic mucosa. Specific alterations in ulcerative colitis. Gastroenterology (1984) 2.06

Adiponectin suppresses colorectal carcinogenesis under the high-fat diet condition. Gut (2008) 2.05

Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest (1983) 2.03

Primary structure of porcine cardiac muscarinic acetylcholine receptor deduced from the cDNA sequence. FEBS Lett (1986) 2.03

Nucleotide sequence of the Bacillus subtilis phoR gene. J Bacteriol (1988) 2.02

Sequence of an intestinal cDNA encoding human gastric inhibitory polypeptide precursor. Proc Natl Acad Sci U S A (1987) 2.02

Parkinson's disease: the presence of Lewy bodies in Auerbach's and Meissner's plexuses. Acta Neuropathol (1988) 2.01

NACP, a presynaptic protein, immunoreactivity in Lewy bodies in Parkinson's disease. Neurosci Lett (1997) 2.01

Abortive bacteriophage T4 head assembly in mutants of Escherichia coli. J Mol Biol (1973) 2.00

Isovaleric acidemia: a new genetic defect of leucine metabolism. Proc Natl Acad Sci U S A (1966) 2.00

Differential contributions of BRCA1 and BRCA2 to early-onset breast cancer. N Engl J Med (1997) 1.97

Neuromyelitis optica preceded by hyperCKemia episode. Neurology (2010) 1.94

Primary B-cell gastric lymphoma: a clinicopathological study of 145 patients. Gastroenterology (1991) 1.94

Visualization, direct isolation, and transplantation of midbrain dopaminergic neurons. Proc Natl Acad Sci U S A (2001) 1.93

Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease. Thorax (1999) 1.93

Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription. Nat Genet (2000) 1.92

Detection and recovery of mycobacteria by a radiometric procedure. J Clin Microbiol (1983) 1.92

Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet (1998) 1.91

Epidemiology of influenza A(H1N1)v virus infection in Japan, May-June 2009. Euro Surveill (2009) 1.91

Successful screening for early esophageal cancer in alcoholics using endoscopy and mucosa iodine staining. Cancer (1995) 1.91

The effect of spo0 mutations on the expression of spo0A- and spo0F-lacZ fusions. Mol Gen Genet (1986) 1.89

Treatment of gallbladder cancer by radical resection. Br J Surg (1999) 1.88

Nuclear magnetic resonance study of antibodies: a multinuclear approach. Methods Enzymol (1994) 1.85

Calcium channel inhibition accelerates polycystic kidney disease progression in the Cy/+ rat. Kidney Int (2007) 1.83

Beta-synuclein gene alterations in dementia with Lewy bodies. Neurology (2004) 1.82

Intestinal antibodies. N Engl J Med (1977) 1.82

Multiple principal sigma factor homologs in eubacteria: identification of the "rpoD box". Science (1988) 1.81

Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol (2001) 1.81

Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med (1985) 1.81

X inactivation in the mouse embryo deficient for Dnmt1: distinct effect of hypomethylation on imprinted and random X inactivation. Dev Biol (2000) 1.80

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD). Dig Liver Dis (2007) 1.79